Skip to main content

Novel Allogeneic CAR-T Products Appear Safe in LBCL and FL

 

Sattva Swarup Neelapu, MD, MD Anderson Cancer Center, Houston, Texas, discusses early results from the ALPHA study suggesting that ALLO-501, a genetically modified anti-CD19 CAR T-cell product, and ALLO-647, an anti-CD52 monoclonal antibody, are safe and may be effective in large B-cell lymphoma (LBCL) or follicular lymphoma (FL). These results were presented at the virtual 2020 ASCO Annual Meeting.